Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Non-Current Debt (2016 - 2025)

Amphastar Pharmaceuticals has reported Non-Current Debt over the past 13 years, most recently at $608.7 million for Q4 2025.

  • Quarterly results put Non-Current Debt at $608.7 million for Q4 2025, up 1.18% from a year ago — trailing twelve months through Dec 2025 was $608.7 million (up 1.18% YoY), and the annual figure for FY2025 was $608.7 million, up 1.18%.
  • Non-Current Debt for Q4 2025 was $608.7 million at Amphastar Pharmaceuticals, roughly flat from $608.6 million in the prior quarter.
  • Over the last five years, Non-Current Debt for AMPH hit a ceiling of $638.2 million in Q3 2023 and a floor of $30.5 million in Q2 2021.
  • Median Non-Current Debt over the past 5 years was $537.6 million (2023), compared with a mean of $355.2 million.
  • Biggest five-year swings in Non-Current Debt: decreased 11.19% in 2021 and later skyrocketed 762.31% in 2023.
  • Amphastar Pharmaceuticals' Non-Current Debt stood at $74.8 million in 2021, then fell by 2.59% to $72.8 million in 2022, then soared by 709.43% to $589.6 million in 2023, then rose by 2.04% to $601.6 million in 2024, then rose by 1.18% to $608.7 million in 2025.
  • The last three reported values for Non-Current Debt were $608.7 million (Q4 2025), $608.6 million (Q3 2025), and $607.7 million (Q2 2025) per Business Quant data.